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A B S T R A C T
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
• To conduct a suite of reviews to assess the effectiveness of restriction of physical means of access as a method of suicide
prevention. These reviews will focus on the method of suicide - jumping, colliding with a train, poisoning, hanging, using a firearm,
using a sharp object, inhaling motor vehicle exhaust, drowning, and charcoal burning.
B A C K G R O U N D
This generic protocol will provide a template for a suite of reviews
assessing the effectiveness for suicide prevention of restricting ac-
cess to commonmeans of suicide. This will allow all reviews to use
standard methods and collect data on the same set of outcomes, so
that evidence from different reviews can be more easily compared.
Interventions to be considered are those intended to restrict the
means to jumping, colliding with a train, poisoning, hanging, us-
ing a firearm, using a sharp object, inhaling motor vehicle exhaust,
and drowning. When possible, we will include evidence restricting
the means to newly emerging methods such as charcoal burning.
This generic protocol will not become a full review but will be
retained permanently as a protocol to inform the production of
all means restriction reviews. Each review that is developed (and
subsequently updated) on the basis of this generic protocol will
include its own intervention-specific background along with more
comprehensive information related to that particular means of
suicide.
Description of the condition
Suicide rates
Worldwide, suicide is recognised as a significant public health
problem. It is estimated that each year around one million people
will die from suicide (mortality rate, 11.4 per 100,000) (WHO
2014). Rates are said to have increased by 60% over the past 45
years, and in countries such as Japan, South Korea, China, and
Taiwan, suicide is the leading cause of death among those aged
15 to 44 years (WHO 2010; WHO 2012). The World Health
Organization (WHO) estimates that suicide represents 1.4% of
the total global burden of disease, and that by 2020, this figure
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will reach 2.4% in countries with market and former socialist
economies (WHO 2008). Self-harm, which includes suicide at-
tempts, is much more common than completed suicide and is a
significant cause of morbidity.
Risk factors/causes
A variety of risk factors for suicide and suicidal behaviour are
known. These include mental disorder (particularly depression
and substance abuse); social, psychological, biological, and genetic
factors; exposure to role models; and adverse life events (Hawton
2009; Mann 2002). Gender and age have been shown to play
an important role in suicide, with higher rates reported in young
men (Wasserman 2005). Men are more likely to choose violent
and highly lethal methods such as firearm suicide or hanging, and
women often choose poisoning or drowning, both of which are
less violent and less lethal (Ajdacic-Gross 2008). However, unlike
suicide, self-harm usually occurs more commonly among females
(Hawton 2008). Whatever the background factors at the point
when a person feels hopeless and potentially suicidal, access to
the means of suicide can be decisive. Availability of means can
lead from suicidal thoughts to a suicidal act, particularly when
impulsive behaviour is a factor. The nature of the method chosen
will influence the outcome (Yip 2012).
Definitions
A range of different terms are used for suicide and suicidal be-
haviour. In the context of this suite of reviews, ’suicidal behaviour’
will be used for any form of deliberate or intentional self-injurious
or self-poisoning behaviour with known suicidal intent. ’Suicide’
will be used to refer to self-injurious or self-poisoning behaviour
with a fatal outcome and known suicidal intent or where that
intent was underdetermined. Self-injurious behaviour with non-
suicidal intent and a non-fatal outcome will be referred to as self-
harm.
Means of suicide
Despite differences between countries, three principal methods
of suicide predominate worldwide (WHO 2014). These include
hanging, using firearms, and poisoning by ingestion of pesticides.
Jumping from a height and using other methods of poisoning
(usually poisoning with drugs) are important alternate methods.
Data from WHO (Ajdacic-Gross 2008) show that hanging was
the predominant method of suicide in most countries included
in the analysis. The highest proportions were around 90% in
men and 80% in women in Eastern Europe (i.e. Estonia, Latvia,
Lithuania, Poland, and Romania). Using a firearm was the most
frequent method in the United States, Argentina, Switzerland,
and Uruguay. In rural Latin American countries (e.g. El Salvador,
Nicaragua, Peru), Asian countries (e.g. the Republic of Korea,
Thailand), and Portugal, poisoning with pesticides was a ma-
jor problem, notably among women. Poisoning with drugs was
common in women from Canada, the Nordic countries, and the
United Kingdom. It was also a common means of male suicide
in these countries. Each individual review will provide detailed
information on various means of suicide.
Description of the intervention
Restricting access to common means of suicide such as firearms or
toxic substances is an effective population level prevention strategy
(Hawton 2005). Restricting access to means is underpinned by
the concept of acute periods of risk for suicidal behaviour, for
example, as might occur when a person with depression is exposed
to an adverse life event. If access to means is restricted at this point,
the chance of survival beyond the stage of acute risk increases.
Evidence from research on near lethal suicide attempts supports
the idea that, at least for a proportion of people, these attempts are
an impulsive response that would not have occurred if the means
had not been readily available (Hawton 2005).
It has been argued that restricting access to one method will lead
to substitution with another. However, evidence suggests that re-
stricting access to means during periods of acute risk can have
an impact on an individual’s likelihood of dying from suicide in
the longer term. In the UK, an often used example is coal gas
(Kreitman 1976). From the late 1950s to the early 1970s, domestic
gas supplies changed from coal gas to non-toxic natural gas. After
the Second World War, suicide rates in the UK had been increas-
ing, and carbon monoxide poisoning via a gas oven was the most
common method. With the change to natural gas, the numbers
of these deaths fell. Despite a slight increase in other methods, the
net effect was a large reduction in suicide deaths.
Studies have also provided evidence of near fatal attempts. A 10-
year follow-up of 94 individuals who survived jumping in front of
an underground (subway) train found that only nine went on to
die from probable suicide. All these deaths occurred within three
years and seven months of the index attempt (O’Donnell 1994).
How the intervention might work
Jumping
Most suicides by jumping occur from high-rise residential build-
ings (Beautrais 2007). Other common sites include bridges, cliffs,
and terraces. A range of studies have demonstrated that construc-
tion of barriers and fencing at high-risk jumping sites, especially
bridges, can lead to a reduction in the number of deaths (Beautrais
2001; Bennewith 2007; Cox 2013; Pelletier 2007; Pirkis 2013;
Pirkis 2015).
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Collision with a train
Suicide by collision with a train is a highly lethal method of death
and accounts for between 1% and 12% of suicides internationally
(Krysinska 2008; van Houwelingen 2010). A study evaluating
the effectiveness of installing platform screen doors as a means
of preventing railway suicides found a significant reduction in
railway suicides following the installation of such barriers (Law
2009). Restricting public access to railway tracks can be achieved
by legislation and by installation of surveillance devices.
Poisoning
By drugs
In the 1970s, a reduction in the prescribing of barbiturates was
associated with a subsequent fall in suicide as a result of barbiturate
poisoning (Carlsten 1996).
Legislation on the packaging of paracetamol and salicylates was in-
troduced in theUK in September 1998; this restricted the number
of tablets that could be sold in a single transaction. Some evidence
suggests that this led to a reduction in the number of tablets taken
in overdose (Hawton 2001), although some authors dispute this
finding (Morgan 2007).
By other means
Pesticide ingestion accounts for an estimated 370,000 suicides
worldwide annually; a disproportionate number occur in low- and
middle-income countries (WHO 2009). Access to pesticides can
be restricted by limiting sales and providing safer storage. Many
high-income countries have already banned the use and export of
the most lethal pesticides, and evidence from countries such as
Jordan and Samoa suggests that such bans are associated with a
subsequent fall in suicides (WHO 2009). Safer pesticide storage,
particularly in developing countries, canbe facilitated by providing
locked boxes; encouraging centralised and communal storage; and
educating pesticide users about the risks associated with their use
and about safe storage and disposal.
Hanging
Hanging is the most common means of suicide worldwide
(Gunnell 2005). Restriction of access to means of hanging is often
not possible at a general population level because the most com-
monly used ligatures and ligature points are universally available
(Sarchiapone 2011). However, in controlled environments such
as hospitals and prisons, restriction of access to means of hanging
can be achieved by the introduction of ’safer (ligature-free) cells’,
ligature-free bedding and clothes for high-risk individuals, and
collapsible ligature points such as shower rails (Gunnell 2005).
Using a firearm
Among males, the proportion of suicides in which firearms are in-
volved ranges from 0.2% in Japan to 60.6% in the United States (
WHO2009). Reducing access to firearms can be achieved through
legislation, enforcement, amnesties, and collection schemes. Leg-
islative measures may include banning certain types of firearms;
licensing and registration schemes for suppliers and owners; mini-
mum waiting periods between licensing and purchasing; safe stor-
age checks; and background checks on and/or psychological test-
ing of those who wish to buy them.
A systematic review of the impact of US firearms legislation on
suicide rates found some studies that showed a reduction but con-
cluded that findings were inconsistent (Hahn 2005).
Using a sharp object
Sharp objects are involved in only a small number of suicides:
2.5% in Japan and 2% in Australia (WHO 2009); however self-
cutting is a common form of deliberate self-harm. Legislation can
be used to limit access. In the United Kingdom, it is an offence to
carry a knife or other sharp object in public without good reason.
Inhaling motor vehicle exhaust
In England and Wales, motor vehicle exhaust deaths reached a
peak at the beginning of the 1990s. In 1993, new legislation re-
quired all new petrol vehicles to be fitted with catalytic converters,
which reduce carbon monoxide emissions. Suicide deaths by mo-
tor vehicle exhaust subsequently declined throughout the 1990s
(Brock 2003).
In theUSA, rates ofmotor vehicle-related carbonmonoxide deaths
declined from 10.0 to 4.9 per million person-years over the period
from 1968 to 1998 (Mott 2002). This decline was associated with
enforcement of the automobile emissions standards set by the 1970
Clean Air Act; the first catalytic converters were introduced in the
USA in 1975.
Drowning
Suicide by drowning ranges from 1% in the USA to 15% to 20%
in Ireland (Lunetta 2014). Drowning is a very accessible method
of suicide, particularly in places with easy access to water bodies.
However, it is difficult to determine whether a drowning death is
due to suicide or occurred by accident (Haw 2016). Continuous
surveillance as well as construction of barriers on bridges could
reduce the number of suicides by drowning.
Charcoal burning
Suicide by charcoal burninghas emerged as a newmeans of suicide,
particularly in Asian societies (Pan 2010). A recent study found
that limiting access to charcoal in major retail outlets was effective
in reducing the rate of suicide by charcoal burning (Yip 2010).
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Why it is important to do this review
Several relevant reviews have been published, although not all were
focused on means restriction.
A systematic review published in 2005 examined the evidence for
effectiveness of specific suicide prevention interventions (Mann
2005). Review authors concluded that restricting access to lethal
means was one of the few interventions for which clear evidence
was available. The difficulty in directly attributing declining sui-
cide rates to a particular means restriction in light of overall trends
and factors, such as increased antidepressant use, was noted.
Evidence on the effectiveness of intentional overdose strategies
was discussed in a review published in 2010 (Guo 2010). These
review authors concluded that the impact of legislation to restrict
access to drugs is inconsistent. They concluded that differences in
impact might have resulted from variation in the methods used.
They suggested that, as well as controlling for confounding factors,
future studies should consider prevalence of suicidal behaviour
and changes in predisposing vulnerabilities and protective factors.
A systematic review published in 2011 found that several factors
could influence an individual’s decision regarding method of sui-
cide, but that substantial support indicates that easy access is sig-
nificant (Sarchiapone 2011). Review authors concluded that re-
striction of means can be particularly effective when a method is
widely used, is widely available, is highly lethal, and cannot easily
be substituted for by a similar method. They noted that restriction
of access should be used in conjunction with other prevention ap-
proaches.
Recent reviews on interventions for self-harm in children, adoles-
cents, and adults found little evidence from which to draw con-
clusions (Hawton 2015a; Hawton 2015b; Hawton 2016). Review
authors recommended that further research should be undertaken
to evaluate effective interventions for prevention of self-harm.
Many people who die from suicide do not seek prior treatment and
can be reached only through population-based strategies. Means
restriction is an important universal approach to suicide preven-
tion and has been included within many national suicide preven-
tion programmes. This current suite of reviews is intended to pro-
vide a systematic and exhaustive search of current available evi-
dence to bring together findings on a variety of interventions to
inform evidence-based policy and practice. In accordance with de-
tails based on the Methodological Expectations of Cochrane In-
tervention Reviews (MECIR) (Higgins 2016), when possible, we
will include descriptions of the effects of these interventions on
different population groups within the community, as well as in
low- and middle-income countries.
O B J E C T I V E S
• To conduct a suite of reviews to assess the effectiveness of
restriction of physical means of access as a method of suicide
prevention. These reviews will focus on the method of suicide -
jumping, colliding with a train, poisoning, hanging, using a
firearm, using a sharp object, inhaling motor vehicle exhaust,
drowning, and charcoal burning.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will include randomised controlled trials (RCTs), cluster-ran-
domised controlled trials, cross-over randomised controlled trials,
and quasi-randomised controlled trials in our suite of reviews.
It is likely that we will find very few, or only very poor-quality,
RCTs that meet our inclusion criteria. In this case, we will include
the best evidence available (Petticrew 2006). We will include con-
trolled intervention studies without randomisation, controlled be-
fore and after studies, and observational studies. If we identify very
few or only very poor-quality controlled studies, we will include
studies using interrupted time series design.
We will consider both published and unpublished studies.
Types of participants
Participant characteristics
We will include men and women (aged 10 and over) of all ethnic-
ities.
Diagnosis
Participants will include individuals exhibiting suicidal behaviour.
For the proposed reviews, we will define suicidal behaviour as
fatal or non-fatal intentional self-harm behaviour, which includes
suicide, attempted suicide, and deliberate self-harm (Silverman
2007).
Co-morbidities
Comorbidity with a mental disorder is an important factor asso-
ciated with risk of suicide (Harris 1997). Participants in the suite
of reviews will include individuals with a diagnosis of mental dis-
order, as well as those for whom a diagnosis had not been made
before the suicide or attempted suicide. We will exclude studies
in which participants have received a diagnosis of intellectual dis-
ability.
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Setting
We will include all settings in our suite of reviews, including com-
munity and institutionalised settings such as prisons, schools, and
hospitals.
Subset data
When eligible subsets of data can be retrieved, we will do so.
Types of interventions
Experimental intervention
We will undertake a suite of reviews in which we will review stud-
ies that assess the impact of restrictions on availability of, or ac-
cess to, means of suicide. These include interventions intended
to restrict the means to jumping, colliding with a train, poison-
ing, hanging, using a firearm, using a sharp object, inhaling mo-
tor vehicle exhaust, drowning, and charcoal burning. Examples of
interventions to be included in each review include construction
of barriers at jumping sites, installation of surveillance devices on
railway tracks, legislation to restrict quantities of paracetamol and
other analgesics, introduction of ligature-free cells in prisons, leg-
islation to reduce access to firearms and sharp objects, legislation
to reduce carbon monoxide emissions in motor vehicles, contin-
uous surveillance around water bodies, and limitation of access to
charcoal in major retail outlets.
We will include universal, selective, and indicated means restric-
tion interventions. Universal interventions are those targeted at
the general public or whole populations and include legislation to
restrict access to means for suicidal behaviour such as ownership
and storage of firearms; and installation of barriers at jumping
sites. Most means restriction interventions are universal. Selective
interventions are targeted at individuals or groups within a pop-
ulation at increased risk of suicidal behaviours and include instal-
lation of barriers on bridges close to psychiatric hospitals and use
of ligature-free cells, bedding, and clothes in prisons. Indicated
interventions are targeted at individuals with known suicidal be-
haviours and include limiting access to medication.
We will not include interventions to educate professionals (who
assess or advise) or to educate the public (on storage or security of
means). We also will not include interventions to restrict cognitive
availability of means of suicide, for example, the impact of media
portrayals, and we will not include interventions aimed at improv-
ing recognition, screening for risk, and treating or understanding
the causes and risk factors of suicidal behaviour (including mental
illness).
Comparator intervention
Comparator interventions or control conditions will include any
other intervention or no intervention. When possible, we will in-
clude head-to-head interventions (e.g. signage on bridges vs struc-
tural changes).
Types of outcome measures
We will include in each individual review the following primary
outcomes. We may include additional review-specific outcomes
(primary or secondary, or both) in individual reviews.
Primary outcomes
Primary outcomes will include the following.
• Rates of suicide or attempted suicide or self-harm.
◦ This outcome will be measured in two ways.
⋄ At population level.
⋄ By the specific method targeted by the means
restriction initiative.
• Study dropouts.
Secondary outcomes
Secondary outcomes will include the following.
• Change in hospital admission rates for specified methods of
attempted suicide or self-harm (including admissions to
specialised liver units and psychiatric units).
• Cost-effectiveness of the interventions.
◦ Of the two current guiding frameworks for inclusion
of economic perspectives in Cochrane Reviews (Shemilt 2013),
we will report this outcome using the brief economic
commentary framework for incorporating economic perspectives
in Cochrane Reviews, rather than performing a full systematic
review of evidence from previously published economic
evaluations.
Timing of outcome assessment
The intervention is expected to have an immediate effect. Out-
comes will be assessed at three time points after the intervention
has been introduced: immediate/short term (one to four weeks),
medium term (three to 12 months), and long term (over a year).
Search methods for identification of studies
Specialised Register of the Cochrane Common
Mental Disorders Group
The Cochrane Common Mental Disorders Group (CCMD)
maintains a specialised register of randomised controlled trials, the
CCMDCTR. This register contains over 40,000 reference records
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(reports of RCTs) for depression, anxiety, bipolar disorder, eating
disorders, self-harm, and other mental disorders within the scope
of this Group. The CCMDCTR is in part a studies-based register,
with > 50% of reference records tagged to c12,500 individually
PICO-coded study records. Reports of trials for inclusion in the
register are collated from (weekly) generic searches of MEDLINE,
Embase, and PsycINFO; quarterly searches of the Cochrane Cen-
tral Register ofControlledTrials (CENTRAL); and review-specific
searches of additional databases. Reports of trials are also sourced
from international trials registries, drug company websites, and
handsearching of key journals, conference proceedings, and other
(non-Cochrane) systematic reviews and meta-analyses.
Details of CCMD’s core search strategies (used to identify RCTs)
can be found on the Group’s website; an example of the core
MEDLINE search is outlined in Appendix 1.
Electronic searches
The CCMD Group’s Information Specialist will cross-search the
CCMDCTR (studies and references register) using the following
search terms tofind reports of randomised controlled trials (RCTs).
#1. means near2 suicid*
#2. (suicid* or parasuicid* or para-suicid* or self-harm* or “self
harm*”)
#3. (restrict* near (access* or availab* or means or method* or
prescription*))
#4. (access* or availab* or lethal* or physical) near (means or
method*)
#5. ((eas* or secure) near access*)
#6. (“drug packag*” or “product packag*” or (pack* near siz*))
#7. (overdos* or “over dos*” or over-dos*) near (drug* or anal-
gesic* or paracetamol or acetaminophen or aspirin or salicyl* or
barbituat* or over-the-counter or “over the counter” or prevent*)
#8. (poison* or self-poison* or “self poison*” or gas or gases or
charcoal or burning or pesticide* or insecticide* or organophosp*)
#9. (“exhaust fume*” or “carbon monoxide” or emission*)
#10. (automobile* or vehicle* or car or cars)
#11. “safe stor*” or “safe room*”
#12. (prison* or jail* or gaol* or detention* or incarcerat* or “se-
cure unit*”)
#13. (drowning* or suffocat* or asphyxia*)
#14. “sharp object*” or knife or knives
#15. (hanging or jump* or leap* or railway* or railroad* or subway
or “sub way” or metro or underground or “tall building*” or “car
park*” or carpark* or high-rise* or “high rise*” or architectur* or
“environment design” or bridge* or cliff*)
#16. (firearm* or “fire arm*” or fire-arm* or gun or guns* or hand-
gun* or “hand-gun*” or hand-gun*)
#17. (structural or physical) NEAR (intervention or barrier)
#18. (barrier* or rail* or net or nets) and (safe* or prevent*)
#19. (#1 or (#2 and (#3 or #4 or #5 or #6 or #7 or #8 or #9 or #
10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18)))
The Information Specialist will search the Cochrane Library, in-
cluding theCochrane Central Register of Controlled Trials (CEN-
TRAL), for additional controlled trials (RCTs, controlled clinical
trials (CCTs)) using a similar set of terms (Appendix 2).
We will conduct complementary searches of the following biblio-
graphic databases (for condition + intervention only, we will apply
no study design filters). We will apply relevant subject headings
(controlled vocabularies) and search syntax to each resource as ap-
propriate.
• Ovid MEDLINE (1946 to date); search strategy listed in
Appendix 3.
• Ovid PsycINFO (all years).
• Ovid Embase (1980 to date).
• Web of Science Core Collection: citation Indexes (all years).
We will search International trial registries via the World Health
Organization trials portal (ICTRP) and ClinicalTrials.gov to iden-
tify unpublished and ongoing studies.
We will apply no restriction on date, language, or publication
status to these searches.
Searching other resources
Grey literature
We will search the following sources of grey literature.
• Networked Digital Library of Theses and Dissertations
(NDLTD).
• ProQuest Dissertations and Theses database.
• National Guideline Clearing House (http://guideline.gov/).
• OpenGrey (http://www.opengrey.eu/).
• Google Scholar.
The search strategy will be broad and will be designed to capture
a range of references.
Reference lists
In addition to the searches outlined above, we will check the ref-
erence lists of all included studies and relevant systematic reviews
to identify additional studies missed during the original electronic
searches (e.g. unpublished or in-press citations). We will also con-
duct a cited reference search on the Web of Science.
Correspondence
We will contact trialists and subject experts to ask for information
on unpublished and ongoing studies, or to request additional trial
data.
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Data collection and analysis
Selection of studies
We will screen all reports and publications identified as the result
of the search for inclusion in the reviews. Two review authors (CO,
AJ) will do this independently for all reviews. Upon review of ti-
tles and abstracts, we will code these reports as ’retrieve’ (eligible,
potentially eligible, or unclear) or ’do not retrieve’. We will ob-
tain the full-text report/publication for each one coded ‘retrieve’.
Two review authors (CO, AJ) will review the full texts to inde-
pendently screen and identify studies for inclusion. We will record
the reasons for exclusion of ineligible studies. Review authors will
resolve disagreements through discussion or, if required, through
consultation with a third review author (KL, KH). We will ex-
clude all duplicate records. When we find multiple reports of the
same study, we will collate them to ensure that each study rather
than each report/publication is the unit of interest in the review.
We will record the selection process in sufficient detail to allow
us to complete a PRISMA flow diagram and ’Characteristics of
excluded studies’ table.
Data extraction and management
Two review authors (CO, AJ) or other named authors where nec-
essary will extract study characteristics and outcome data and will
enter this information into a data collection form that has been
piloted specifically for this suite of reviews.
One review author will enter details of each included study into
the Cochrane software Review Manager 5.3 (RevMan 2014), and
a second author will review the data. We will record data on the
following (Armstrong 2007).
• Methods: study design, total duration of study, details of
any ’run-in’ period, number of study centres and locations, study
setting, withdrawals of the intervention, and dates of the study.
• Participants: N, mean age, age range, gender, severity of
condition, diagnostic criteria, inclusion criteria, and exclusion
criteria.
• Interventions: intervention, comparison.
• Outcomes: primary and secondary outcomes specified and
collected, time points reported.
• Statistical analysis.
• Results.
• Limitations.
• Notes: funding for trial and notable conflicts of interest of
trial authors.
We will separate eligible studies into the following categories for
purposes of data extraction.
• Jumping (to include buildings and bridges).
• Collision with a train.
• Suicide on roads.
• Poisoning.
• Hanging.
• Use of a firearm.
• Use of a sharp object.
• Motor vehicle exhaust.
• Drowning.
• Charcoal burning.
When data are not reported in a useable way, we will note this
in the ’Characteristics of included studies’ table. We will resolve
disagreements first by consensus and when this fails by consulta-
tion with a third review author (KL or KH). One review author
(CO) will be nominated as the person who will transfer data into
Review Manager (RevMan 2014). Data entered will be double-
checked for accuracy by comparing data presented in the system-
atic review versus data provided in the study reports. Additionally,
a second review author (AJ) will spot-check study characteristics
for accuracy against the trial report.
Main comparisons
For each review, we will conduct the following main comparisons.
We will stratify graphs according to type of intervention.
• Universal intervention versus no intervention.
• Universal intervention versus any other intervention.
• Selective intervention versus no intervention.
• Selective intervention versus any other intervention.
• Indicated intervention versus no intervention.
• Indicated intervention versus any other intervention.
Assessment of risk of bias in included studies
Two review authors (CO, AJ) will independently assess risk of
bias for each study included in the proposed suite of reviews. We
hypothesise that our included studies will consist of randomised
and non-randomised studies; therefore we will base our criteria
on Cochrane’s tool for assessing risk of bias in RCTs (Higgins
2011) and Cochrane’s risk of bias tool for non-randomised studies
(Sterne 2016). We will resolve disagreements in the first instance
by consensus and when this fails through involvement of a third
review author (KL, KH).
For randomised trials, we will base our assessment on the following
domains.
• Random sequence generation.
• Allocation concealment.
• Blinding of participants and personnel.
• Blinding of outcome assessment.
• Incomplete outcome data.
• Selective outcome reporting.
• Other bias.
We will judge each potential source of bias as having high, low,
or unclear risk and will provide a supporting quotation from the
study report together with a justification for our judgement in the
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’Risk of bias’ table. We will summarise risk of bias judgements
across different studies for each of the domains listed. We will
consider blinding separately for different key outcomes when nec-
essary (e.g. for unblinded outcome assessment, risk of bias for all-
cause mortality may be very different than for a patient-reported
pain scale). When information on risk of bias is related to unpub-
lished data or correspondence with a trialist, we will note this in
the ’Risk of bias’ table.
When considering treatment effects, we will take into account the
risk of bias for studies that contribute to that outcome.
Assessment of methodological quality of included studies
Two review authors (CO, AJ) will independently appraise studies.
We will refer to a third review author (KL, KH) any disagreements
that cannot be resolved. When necessary, we will contact study
authors for further information.
In addition to using the Cochrane ’Risk of Bias’ tool, we plan to
use the ’Risk of Bias in Non-randomised Studies of Interventions
(ROBINS-I)’ tool to assess risk of bias for each included study
(Sterne 2016). This new tool can be used to evaluate risk of bias
in estimates of the comparative effectiveness of interventions from
studies that did not use randomisation to allocate units to com-
parison groups (Sterne 2016). This tool assesses studies on seven
domains of bias.
• Confounding.
• Selection bias.
• Bias in measurement classification of interventions.
• Bias due to deviation from intended interventions.
• Bias due to missing data.
• Bias in measurement of outcomes.
• Bias in selection of the reported result.
Application of assessment criteria will be piloted to ensure that
criteria can be applied consistently. We will assess inter-rater re-
liability using the kappa statistic. We will resolve disagreements
on data extraction by consensus discussion, following review by a
third assessor.
Measures of treatment effect
Dichotomous data
We will analyse dichotomous data as risk ratios (RRs) with 95%
confidence intervals (CIs).
Continuous data
We will analyse continuous data as mean differences (MDs) if
trials measure outcomes the same way. We will use standardised
mean differences (SMDs) to combine trials that measure the same
outcome but use different methods. We will enter data presented
as a scale with a consistent direction of effect.
We will undertake meta-analyses only when this is meaningful
(i.e. when treatments, participants, and the underlying clinical
question are similar enough for pooling to make sense).
We will narratively describe skewed data reported as medians and
interquartile ranges.
Unit of analysis issues
Cluster-randomised trials
If identified, we will include in analyses cluster-randomised trials
that meet all eligibility criteria along with individually randomised
trials. We will adjust sample sizes using the methods described
in the Cochrane Handbook for Systematic Reviews of Interventions
(Higgins 2011) based on an estimate of the intracluster correla-
tion coefficient (ICC) derived from that trial (if available), from
a similar trial, or from a study of a similar population. If we use
ICCs from other sources, we will report this and will undertake
sensitivity analyses to investigate the effect of variation in ICCs. If
we identify both cluster-randomised and individually randomised
trials, we will plan to synthesise any relevant information. We will
consider combining the results from both types of trials if we note
little heterogeneity between study design and if we consider in-
teraction between the effect of the intervention and the choice of
randomisation unit to be unlikely. We will acknowledge hetero-
geneity in the randomisation unit and will perform a sensitivity
analysis to investigate effects of the randomisation unit. We will
take this approach only if a cluster RCT has been incorrectly anal-
ysed, as though the unit of allocation had been randomised at the
level of the individual participant.
Cross-over trials
If we identify any cross-over trials, we will consider the first period
of measurement only and will analyse study results together with
those derived from parallel-group studies.
Studies with multiple treatment groups
When multiple trial arms are reported in a single trial, we will
combine the arms to create a single pair-wise comparison when
possible (Higgins 2011). If this is not possible, wewill use alternate
methods set out in theCochrane Handbook for Systematic Reviews
of Interventions to avoid double-counting of study participants
(Higgins 2011).
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Dealing with missing data
For included studies, wewill note levels of attrition.Wewill explore
the impact of including studies with high levels of missing data
in the overall assessment of treatment effect by using sensitivity
analysis.
For all outcomes, review authors will carry out analyses, as far
as possible, on an intention-to-treat basis (i.e. they will attempt
to include in analyses all participants randomised to each group
and will analyse all participants in the group to which they were
allocated, regardless of whether or not they received the allocated
intervention). The denominator for each outcome in each trial
will be the number randomised minus the number of participants
whose outcomes are known to be missing.
When important data or information about the study design is
missing, we will contact investigators or study sponsors to verify
key study characteristics and to obtain missing numerical outcome
datawhen possible (e.g. when a study is identified as abstract only).
We will document all correspondence with trialists and will report
in the review which trialists responded to our requests.
Assessment of heterogeneity
Review authors will assess heterogeneity by using appropriate sta-
tistical tests. We will use the I2 statistic to assess heterogeneity be-
tween trials (Higgins 2011). Thresholds for interpreting I2 are as
follows.
• 0% to 40%: might not be important.
• 30% to 60%: may represent moderate heterogeneity.
• 50% to 90%: may represent substantial heterogeneity.
• 75% to 100%: considerable heterogeneity.
If we detect substantial heterogeneity, we will explore possible
causes and will perform subgroup analyses for main outcomes. We
will use a random-effects model to allow for expected heterogene-
ity. Effect estimates will be weighted by the inverse of their vari-
ance, with greater weight given to larger trials. We could carry out
a meta-analysis of similar interventions to provide an indication
of the direction if not the size of any effect.
We will give consideration to meta-analysis of RCTs, quasi-RCTs,
and studies of other designs. When not appropriate, we will sum-
marise studies in tables and by narrative synthesis.
Assessment of reporting biases
If 10 or more studies report the same outcome of interest, we will
generate funnel plots to investigate the relationship between study
power and effect size. We will consider randomised and non-ran-
domised studies separately. An asymmetrical plot may indicate bi-
ases such as publication bias, poor quality of smaller studies, or
true differences related to smaller studies (e.g. different popula-
tions). We will explore possible reasons for any asymmetry de-
tected (Egger 1997).
Data synthesis
We will carry out statistical analysis using Review Manager soft-
ware (RevMan 2014). When more than one study examines the
same intervention and we judge study populations andmethods as
being sufficiently similar, we will conduct a meta-analysis to pro-
vide an overall estimate of treatment effect. Because of the varied
nature of the interventions reviewed (including interventions and
settings), we will use a random-effects meta-analysis model when
combining data.We will not combine results fromRCTs and non-
RCTs in a meta-analysis, nor will we pool estimates from non-
randomised studies with those from studies of different designs.
When we deem that meta-analysis is inappropriate owing to sig-
nificant heterogeneity, we will provide a narrative synthesis of re-
sults.
Subgroup analysis and investigation of heterogeneity
Suicidal behaviour is strongly associated with a history of self-
harm or mental disorder. Effect sizes in these high-risk groups are
generally higher than in the general population. Therefore, when
data are available, we will perform the following subgroup analyses
for all reviews.
• Comorbidity versus no comorbidity.
• History of self-harm versus no known history of self-harm.
• Diagnosis of mental disorder versus no known history of
mental disorder.
• Adults versus people younger than 18 years.
We will use only primary outcomes in the subgroup analysis.
For random-effects meta-analyses, we will examine differences be-
tween subgroups by visually inspecting the subgroup’s confidence
intervals; non-overlapping CIs suggest a statistically significant
difference in treatment effect between subgroups. We will pro-
vide totals and subtotals for subgroup analyses. We will assess
subgroup differences by using the interaction tests available in
RevMan (RevMan 2014).
When we find evidence of inconsistency between subgroups, we
will report this in the text and will present results by quoting the
Chi² statistic and the P value, along with the interaction I² statistic
value.Wewill explore subgroup differences as ameans of exploring
heterogeneity.
Sensitivity analysis
We will conduct sensitivity analyses to examine the effects of ex-
cluding from the analysis studies judged to be at high risk of bias
(e.g. by excluding studies with high or unclear risk of selection
bias (random sequence generation and allocation concealment),
incomplete outcome data, substantial levels of heterogeneity). If
exclusion of these studies does not substantially alter the direction
of effect or the precision of effect estimates, we will include all
relevant data from these studies in the analysis. We will consider
randomised and non-randomised studies separately.
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’Summary of findings’ table
We will summarise the body of evidence for all critical and im-
portant outcomes using the Grading of Recommendations As-
sessment, Development and Evaluation (GRADE) system. The
GRADE approach defines the quality of a body of evidence as the
extent to which one can be confident that an estimate of effect or
association is close to the quantity of specific interest (Schünemann
2011). We will summarise the assessment in a ’Summary of find-
ings’ table created with GRADEpro software. We shall assess the
long-term (over one year) quality of the body of evidence related
to the following outcomes.
• Rates of suicide or attempted suicide (both at the
population level and by the specific method targeted by the
means restriction initiative).
• Change in hospital admission rates for specified methods of
attempted suicide (including admissions to specialised liver units
and psychiatric units).
• Cost-effectiveness of interventions.
• Study dropouts.
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A P P E N D I C E S
Appendix 1. Cochrane Specialised Register - core MEDLINE search strategy
Core search strategy used to inform the Cochrane Common Mental Disorders Group’s Specialised Register: OVID MEDLINE
A weekly search alert based on condition + RCT filter only
1. [MeSH Headings]:
eating disorders/ or anorexia nervosa/ or binge-eating disorder/ or bulimia nervosa/ or female athlete triad syndrome/ or pica/ or
hyperphagia/ or bulimia/ or self-injurious behavior/ or self mutilation/ or suicide/ or suicidal ideation/ or suicide, attempted/ or
mood disorders/ or affective disorders, psychotic/ or bipolar disorder/ or cyclothymic disorder/ or depressive disorder/ or depression,
postpartum/ or depressive disorder, major/ or depressive disorder, treatment-resistant/ or dysthymic disorder/ or seasonal affective
disorder/ or neurotic disorders/ or depression/ or adjustment disorders/ or exp antidepressive agents/ or anxiety disorders/ or agoraphobia/
or neurocirculatory asthenia/ or obsessive-compulsive disorder/ or obsessive hoarding/ or panic disorder/ or phobic disorders/ or stress
disorders, traumatic/ or combat disorders/ or stress disorders, post-traumatic/ or stress disorders, traumatic, acute/ or anxiety/ or anxiety,
castration/ or koro/ or anxiety, separation/ or panic/ or exp anti-anxiety agents/ or somatoform disorders/ or body dysmorphic disorders/
or conversion disorder/ or hypochondriasis/ or neurasthenia/ or hysteria/ ormunchausen syndrome by proxy/ ormunchausen syndrome/
or fatigue syndrome, chronic/ or obsessive behavior/ or compulsive behavior/ or behavior, addictive/ or impulse control disorders/
or firesetting behavior/ or gambling/ or trichotillomania/ or stress, psychological/ or burnout, professional/ or sexual dysfunctions,
psychological/ or vaginismus/ or Anhedonia/ or Affective Symptoms/ or *Mental Disorders/
2. [Title/ Author Keywords]:
(eating disorder* or anorexia nervosa or bulimi* or binge eat* or (self adj (injur* or mutilat*)) or suicide* or suicidal or parasuicid* or
mood disorder* or affective disorder* or bipolar i or bipolar ii or (bipolar and (affective or disorder*)) or mania or manic or cyclothymic*
or depression or depressive or dysthymi* or neurotic or neurosis or adjustment disorder* or antidepress* or anxiety disorder* or
agoraphobia or obsess* or compulsi* or panic or phobi* or ptsd or posttrauma* or post trauma* or combat or somatoform or somati#
ation or medical* unexplained or body dysmorphi* or conversion disorder or hypochondria* or neurastheni* or hysteria or munchausen
or chronic fatigue* or gambling or trichotillomania or vaginismus or anhedoni* or affective symptoms or mental disorder* or mental
health).ti,kf.
3. [RCT filter]:
(controlled clinical trial.pt. or randomized controlled trial.pt. or (randomi#ed or randomi#ation).ab,ti. or randomly.ab. or (random*
adj3 (administ* or allocat* or assign* or class* or control* or determine* or divide* or distribut* or expose* or fashion or number* or
place* or recruit* or subsitut* or treat*)).ab. or placebo*.ab,ti. or drug therapy.fs. or trial.ab,ti. or groups.ab. or (control* adj3 (trial* or
study or studies)).ab,ti. or ((singl* or doubl* or tripl* or trebl*) adj3 (blind* or mask* or dummy*)).mp. or clinical trial, phase ii/ or
clinical trial, phase iii/ or clinical trial, phase iv/ or randomized controlled trial/ or pragmatic clinical trial/ or (quasi adj (experimental
or random*)).ti,ab. or ((waitlist* or wait* list* or treatment as usual or TAU) adj3 (control or group)).ab.)
4. (1 and 2 and 3)
Records are screened for reports of RCTs within the scope of the Cochrane Common Mental Disorders Group. Secondary reports of
RCTs are tagged to the appropriate study record.
Similar weekly search alerts are also conducted on OVID EMBASE and PsycINFO, using relevant subject headings (controlled
vocabularies) and search syntax, appropriate to each resource
Appendix 2. The Cochrane Library search
#1. “means restriction” or (means near/2 suicid*)
#2. (suicid* or parasuicid* or para-suicid* or “self harm*” or self-harm*)
#3. MeSH descriptor: [SUICIDE] explode all trees
#4. MeSH descriptor: [SELF-INJURIOUS BEHAVIOR] this term only
#5. (#2 or #3 or #4)
#6. (restrict* near (access* or availab* or means or method* or prescription*))
#7. (access* or availab* or lethal* or physical) near/2 (means or method*)
#8. (“drug packag*” or “product packag*” or (pack* near siz*))
#9. “over the counter”
#10. MeSH descriptor: [PRODUCT PACKAGING] this term only
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#11. MeSH descriptor: [DRUG PACKAGING] this term only
#12. MeSH descriptor: [LEGISLATION, DRUG] this term only
#13. MeSH descriptor: [ACETAMINOPHEN] this term only and with qualifier(s): [Supply & distribution - SD]
#14. (overdos* or over dos* or over-dos*) near/2 (drug* or analgesic* or paracetamol or acetaminophen or aspirin or salicyl* or barbituat*
and prevent*)
#15. MeSH descriptor: [DRUG OVERDOSE] this term only and with qualifier(s): [Prevention & control - PC]
#16. (poison* or self-poison* or “self poison*” or gas or gases or charcoal or burning or pesticide* or insecticide* or organophosp*)
#17. (“exhaust fume*” or “carbon monoxide” or emission*)
#18.(automobile* or vehicle* or car or cars)
#19. MeSH descriptor: [GAS POISONING] explode all trees
#20. MeSH descriptor: [ORGANOPHOSPHATE POISONING] this term only
#21. MeSH descriptor: [PESTICIDES] explode all trees
#22. MeSH descriptor: [AGRICULTURE] this term only
#23. MeSH descriptor: [RURAL POPULATION] this term only
#24. MeSH descriptor: [POISONING] this term only
#25. MeSH descriptor: [CHARCOAL] this term only
#26. MeSH descriptor: [VEHICLE EMISSIONS] this term only and with qualifier(s): [Legislation & jurisprudence - LJ, Poisoning -
PO]
#27. “safe* stor*” or “safe* room*”
#28. MeSH descriptor: [ASPHYXIA] this term only
#29. MeSH descriptor: [DROWNING] this term only
#30. (asphyxia* or suffocat* or drowning*)
#31. (prison* or jail* or gaol* or detention* or incarcerat* or “secure unit*”)
#32. MeSH descriptor: [PRISONS] explode all trees
#33. “sharp object*” or knife or knives
#33. MeSH descriptor: [WOUNDS and INJURIES] this term only and with qualifier(s): [Prevention & control - PC]
#34. (hanging or jump* or leap* or railway* or railroad* or subway or “sub way” or metro or underground or “tall building*” or “car
park*” or carpark* or high-rise* or “high rise*” or architectur* or bridge* or cliff*)
#35. (barrier* or rail* or net or nets) near (safe* or prevent*)
#36. (structural or physical) next (intervention or barrier)
#37. MeSH descriptor: [ENVIRONMENT DESIGN] this term only
#38. MeSH descriptor: [ARCHITECTURAL ACCESSIBILITY] this term only
#39. (firearm* or “fire arm*” or fire-arm* or gun or guns* or handgun* or “hand-gun*” or hand-gun*)
#40. MeSH descriptor: [FIREARMS] this term only
#41. MeSH descriptor: [URBAN POPULATION] this term only
#42. MeSH descriptor: [PUBLIC POLICY] this term only
#43. MeSH descriptor: [MASS MEDIA] this term only
#44. (#1 or (#5 and (#6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21 or #
22 or #23 or #24 or #25 or #26 or #27 or #28 or #29 or #30 or #31 or #32 or #33 or #34 or #35 or #36 or #37 or #38 or #39 or #40
or #41 or #42 or #43)))
#45. SR-DEPRESSN or HS-DEPRESSN
#46. (#42 not #43)
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Appendix 3. Ovid MEDLINE search
A precision maximizing search of MEDLINE will be conducted (no study design filters will be applied)
1. SUICIDE/ or SUICIDAL IDEATION/ or SUICIDE, ATTEMPTED/
2. SELF-INJURIOUS BEHAVIOR/
3. (suicid* or parasuicid* or para suicid*).tw.
4. or/1-3
5. (restrict* adj3 (access or mean*1 or method*1)).tw.
6. (lethal* adj3 (mean*1 or method*1)).tw.
7. DRUG PACKAGING/
8. LEGISLATION, DRUG/
9. ACETAMINOPHEN/sd [Supply & Distribution]
10. exp ANALGESICS/lj, sd [Legislation & Jurisprudence, Supply & Distribution]
11. VEHICLE EMISSIONS/lj, po [Legislation & Jurisprudence, Poisoning]
12. “WOUNDS AND INJURIES”/lj, pc [Legislation & Jurisprudence, Prevention & Control]
13. ENVIRONMENT DESIGN/
14. or/4-13
15. ARCHITECTURAL ACCESSIBILITY/
16. RAILROADS/
17. DRUG OVERDOSE/
18. (poison* or paracetamol or acetominaphen or analgesic* or over-the-counter).ti.
19. FIREARMS/
20. WOUNDS, GUNSHOT/
21. (firearm* or gun or guns or handgun* or hand gun*).ti.
22. exp PESTICIDES/
23. POISONING/ or GAS POISONING/ or CARBONMONOXIDE POISONING/ or ORGANOPHOSPHATE POISONING/
24. CHARCOAL/
25. (pesticide* or charcoal or rural*).ti.
26. AGRICULTURE/
27. RURAL POPULATION/
28. URBAN POPULATION/
29. PRISONS/
30. (hanging or jump* or leap* or bridge*1 or barrier*1 or net*1 or railway* or railroad* or subway).ti.
31. ASPHYXIA/
32. DROWNING/
33. (asphyxia* or suffocat* or drowning*).ti.
34. PUBLIC POLICY/
35. MASS MEDIA/
36. or/15-35
37. prevention & control.fs.
38. ((prevent* and suicid*) or ((preventive or prevention) and (intervention* or program*)) or (prevention and control)).mp.
39. SURVIVAL ANALYSIS/ or SURVIVAL RATE/
40. or/37-39
41. 36 and 40
42. (4 and (14 or 41))
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